Liu Jiao, Chen Ruixuan, Zhou Shiyu, Guo Zhixin, Su Licong, Cao Lisha, Li Yanqin, Zhang Xiaodong, Luo Fan, Xu Ruqi, Gao Qi, Lin Yuxin, Xu Xin, Nie Sheng
Division of Nephrology, National Clinical Research Center for Kidney Disease, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, 1838 N Guangzhou Ave, Guangzhou, 510515, China.
BMC Nephrol. 2025 Jan 8;26(1):12. doi: 10.1186/s12882-024-03925-z.
The effects of acute kidney injury (AKI) on liver-related outcomes in patients with hepatitis B virus (HBV) infection remain unclear. The study aimed to evaluate the association between AKI with liver-related mortality and complications in patients with HBV infection.
The multicenter, retrospective cohort study included Chinese adults with HBV infection from 24 regional central hospitals between January 2000 and December 2022. AKI was defined as a ≥ 26.5 μmol/l increase in serum creatinine concentration within 48 h, or a ≥ 50% increase over the baseline within 7 days. The primary outcome was post-discharge liver-related mortality, while the secondary outcome was a composite of new-onset liver cirrhosis and hepatocellular carcinoma. Cox proportional hazard model was employed for analyses.
Of the 86,204 inpatients with HBV infection and without liver cancer or cirrhosis at baseline, 4407(5.1%) patients experienced AKI. During a mean follow-up of 4.6 ± 2.4 years, 334 (0.4%) patients died of liver-related events. After adjustment, AKI during hospitalization was significantly associated with a higher risk of liver-related mortality after discharge (adjusted hazard ratio (HR), 1.78; 95% confidence intervals (CI), 1.26-2.51, P = 0.001), especially in those with severe AKI. Similarly, AKI was associated with a higher risk of cirrhosis or new-onset hepatocellular carcinoma (adjusted HR, 1.33; 95%CI, 1.10-1.60, P = 0.004). The association between AKI and liver-related outcomes remained consistent across different subgroups.
AKI during hospitalization was associated with substantial increased risk of liver-related mortality and incident liver-related complication. Our findings highlight the importance of monitoring AKI in patients with HBV infection for tailoring personalized treatments.
急性肾损伤(AKI)对乙型肝炎病毒(HBV)感染患者肝脏相关结局的影响尚不清楚。本研究旨在评估AKI与HBV感染患者肝脏相关死亡率及并发症之间的关联。
这项多中心回顾性队列研究纳入了2000年1月至2022年12月期间来自24家地区中心医院的成年HBV感染患者。AKI定义为48小时内血清肌酐浓度升高≥26.5μmol/l,或7天内较基线水平升高≥50%。主要结局是出院后肝脏相关死亡率,次要结局是新发肝硬化和肝细胞癌的复合结局。采用Cox比例风险模型进行分析。
在86204例基线时无肝癌或肝硬化的HBV感染住院患者中,4407例(5.1%)发生AKI。在平均4.6±2.4年的随访期间,334例(0.4%)患者死于肝脏相关事件。调整后,住院期间的AKI与出院后肝脏相关死亡风险显著升高相关(调整后风险比(HR)为1.78;95%置信区间(CI)为1.26 - 2.51,P = 0.001),尤其是在严重AKI患者中。同样,AKI与肝硬化或新发肝细胞癌风险升高相关(调整后HR为1.33;95%CI为1.10 - 1.60,P = 0.004)。AKI与肝脏相关结局之间的关联在不同亚组中保持一致。
住院期间的AKI与肝脏相关死亡率及新发肝脏相关并发症风险大幅增加相关。我们的研究结果凸显了在HBV感染患者中监测AKI以制定个性化治疗方案的重要性。